Gesellschaft mit beschränkter Haftung

Automotive Transmission Dynamometer Market size in North America to grow by USD 565.05 million from 2023 to 2028; Future Scope and Innovations

Retrieved on: 
Thursday, January 11, 2024

The North America Automotive Transmission Dynamometer Market is driven by increased R&D investments due to cost pressures faced by automotive OEMs, spurred by compliance with environmental and safety standards.

Key Points: 
  • The North America Automotive Transmission Dynamometer Market is driven by increased R&D investments due to cost pressures faced by automotive OEMs, spurred by compliance with environmental and safety standards.
  • The automotive transmission dynamometer market in North America is fragmented owing to the presence of many global and regional companies.
  • Major Challenges - The North America Automotive Transmission Dynamometer Market confronts a notable challenge due to a shortage of skilled personnel adept in dynamometer testing, impacting Transmission Efficiency and Automotive Test Systems.
  • The automotive clutch actuator market size is estimated to grow by USD 7,601.28 million at a CAGR of 11.68% between 2023 and 2028.

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Retrieved on: 
Tuesday, January 9, 2024

The infusion of fresh capital is set to boost the progress of Acousia's Kv7.4 activator programs, with a focus on advancing the ongoing clinical development of ACOU085.

Key Points: 
  • The infusion of fresh capital is set to boost the progress of Acousia's Kv7.4 activator programs, with a focus on advancing the ongoing clinical development of ACOU085.
  • ACOU085 is a proprietary, small-molecule, etiology-agnostic otoprotective drug candidate, which recently entered Phase 2 clinical testing for the prevention of chemotherapy-induced hearing loss and sensory hair cell death in cancer patients.
  • The significant otoprotective potential of ACOU085 is broadly supported by results from a number of preclinical studies in relevant models.
  • Our lead candidate ACOU085, currently in Clinical Phase 2, aims to set a new standard for treating acute and subacute forms of hearing loss."

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Retrieved on: 
Tuesday, January 9, 2024

The infusion of fresh capital is set to boost the progress of Acousia's Kv7.4 activator programs, with a focus on advancing the ongoing clinical development of ACOU085.

Key Points: 
  • The infusion of fresh capital is set to boost the progress of Acousia's Kv7.4 activator programs, with a focus on advancing the ongoing clinical development of ACOU085.
  • ACOU085 is a proprietary, small-molecule, etiology-agnostic otoprotective drug candidate, which recently entered Phase 2 clinical testing for the prevention of chemotherapy-induced hearing loss and sensory hair cell death in cancer patients.
  • The significant otoprotective potential of ACOU085 is broadly supported by results from a number of preclinical studies in relevant models.
  • Our lead candidate ACOU085, currently in Clinical Phase 2, aims to set a new standard for treating acute and subacute forms of hearing loss."

E-bike Battery Market to increase by USD 2.12 billion from 2022 to 2027, BMZ Holding GmbH, Coslight India Telecom Pvt. Ltd., Giant Manufacturing Co. Ltd. and more among key companies- Technavio

Retrieved on: 
Friday, January 5, 2024

NEW YORK , Jan. 4, 2024 /PRNewswire/ -- The e-bike battery market is expected to grow by USD 2.12 billion from 2022 to 2027.

Key Points: 
  • NEW YORK , Jan. 4, 2024 /PRNewswire/ -- The e-bike battery market is expected to grow by USD 2.12 billion from 2022 to 2027.
  • In addition, the growth momentum of the market will progress at a CAGR of 6.46% during the forecast period, according to Technavio.
  • The longer shelf life of Li-ion battery when compared with other battery technologies is notably driving the e-bike battery market.
  • We provide a detailed analysis of 20 companies operating in the e-bike battery market including  BMZ Holding GmbH, Coslight India Telecom Pvt.

Last Call for Companies to Apply to the World’s Largest Accelerator for Technologies Enabled by Optics, Photonics, and Imaging

Retrieved on: 
Wednesday, January 3, 2024

Participation in the Rochester, NY based accelerator is mostly remote, with select weeks in person for instructional workshops and pitches to investor groups.

Key Points: 
  • Participation in the Rochester, NY based accelerator is mostly remote, with select weeks in person for instructional workshops and pitches to investor groups.
  • Companies accepted into Luminate’s portfolio in the past have been from diverse industries, including autonomous vehicles, augmented reality/virtual reality, climate tech, communications, defense, entertainment, biotech/life sciences, quantum computing, security, and more.
  • Select startups can also have the opportunity to attend Luminate and Silicon Catalyst’s incubator program concurrently.
  • Members also benefit from working alongside peer OPI startups in the program, leveraging best practices, and helping each other toward success.

Human medicines European public assessment report (EPAR): Mevlyq, eribulin, Status: Opinion

Retrieved on: 
Tuesday, January 2, 2024

Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.

Key Points: 
  • Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.
  • Since Mevlyq is administered intravenously and is 100% bioavailable, a bioequivalence study versus the reference product Halaven was not required.
  • Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
  • - Marketing authorisation applicant
    - YES Pharmaceutical Development Services GmbH
    - Opinion adopted
    - 14/12/2023
    - Opinion status
    - Positive

EQS-News: Kapsch TrafficCom AG: Result for the first half of 2023/24.

Retrieved on: 
Saturday, December 30, 2023

In addition, the projects that Kapsch TrafficCom has recently won and is still expecting will strengthen the business in the coming years.

Key Points: 
  • In addition, the projects that Kapsch TrafficCom has recently won and is still expecting will strengthen the business in the coming years.
  • Accordingly, autoTicket GmbH, a joint venture between Kapsch TrafficCom and CTS Eventim, received an amount of EUR 243 million from the Federal Republic of Germany.
  • As a result, EBIT was negatively impacted in the amount of EUR 9 million (previous year: EUR 8 million).
  • Excluding the effects of the settlement in Germany, Kapsch TrafficCom recorded a slightly positive business development in the first half of the year with an EBIT of EUR 1 million.

EQS-News: paragon confirms nine-month figures

Retrieved on: 
Saturday, December 30, 2023

paragon increased its revenue in the first nine months of 2023 to EUR 122.0 million (previous year: EUR 118.5 million) and at the same time further reduced its net debt.

Key Points: 
  • paragon increased its revenue in the first nine months of 2023 to EUR 122.0 million (previous year: EUR 118.5 million) and at the same time further reduced its net debt.
  • EBITDA from discontinued operations (including the effect from the deconsolidation of paragon semvox GmbH) amounted to EUR 7.6 million, meaning that the paragon Group's total EBITDA after nine months amounted to EUR 23.8 million (prior-year period: EUR 12.0 million).
  • As announced, paragon began the stock exchange buyback of its 2017/2027 bonds (ISIN: DE000A2GSB86; WKN: A2GSB8) on November 6, 2023.
  • The plan is for paragon to supply VDL Netcar, ElectricBrands' contract manufacturer, with traction batteries for the XBUS light commercial vehicle from 2025.

EQS-News: DF Deutsche Forfait Group obtains preliminary injunction against Varengold Bank AG

Retrieved on: 
Saturday, December 30, 2023

The credit balance of EUR 5,5 million blocked since June 14, 2023 must be paid out

Key Points: 
  • The credit balance of EUR 5,5 million blocked since June 14, 2023 must be paid out
    Cologne / Hamburg, December 19, 2023 - Deutsche Forfait GmbH is a subsidiary of DF Deutsche Forfait AG (ISIN: DE000A2AA204) and obtained a preliminary injunction against Varengold Bank AG before the Hamburg Regional Court on December 15, 2023.
  • The Regional Court ordered Varengold Bank AG to transfer the retained credit balance of Deutsche Forfait GmbH in the amount of EUR 5.5 million.
  • Deutsche Forfait GmbH is a customer of Varengold Bank AG.
  • Dr. Behrooz Abdolvand, CEO of DF Deutsche Forfait AG, welcomes the court's decision: "We are pleased that the court has ordered Varengold Bank AG to execute our transfer orders.

Match Maison Unveils Pioneering Approach to International Dating Led by Elena Sachs

Retrieved on: 
Wednesday, December 13, 2023

Zurich, Switzerland--(Newsfile Corp. - December 13, 2023) -  Under Elena Sachs' leadership, Match Maison, a professional matchmaking service founded on October 15, 2023, has updated its matchmaking approach to focus on Zurich, Geneva, and London.

Key Points: 
  • Zurich, Switzerland--(Newsfile Corp. - December 13, 2023) -  Under Elena Sachs' leadership, Match Maison, a professional matchmaking service founded on October 15, 2023, has updated its matchmaking approach to focus on Zurich, Geneva, and London.
  • Match Maison's new approach moves beyond traditional algorithmic matches to align individual preferences and values for meaningful connections.
  • The first match in October and all matches since have been successful so far, showing the method's effectiveness.
  • For more information about Match Maison's refined matchmaking approach and membership options, please visit Match Maison's website .